CSF amyloid 1-42 predicts cognitive decline in Parkinson disease
نویسندگان
چکیده
منابع مشابه
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.
OBJECTIVE Measures of neuronal damage/dysfunction are likely good surrogates for disease progression in Alzheimer disease (AD). CSF markers of neuronal injury may offer utility in predicting disease progression and guiding prognostic and outcome assessments in therapeutic trials. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. We here investig...
متن کاملCSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
OBJECTIVE To characterize biological and technical factors which influence cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker levels, including the presence of apolipoprotein E (APOE) ε4 allele, AD diagnosis, Aβ-binding proteins, sample processing, and preanalytical handling. METHODS CSF was collected from 140 subjects with normal cognition, mild cognitive impairment, AD, and non-AD...
متن کاملThe rate of cognitive decline in Parkinson disease.
OBJECTIVES To measure the rate and predictors of change on the Mini-Mental State Examination in patients with Parkinson disease (PD) and to compare that change with the Mini-Mental State Examination changes of patients with Alzheimer disease and nondemented subjects. PATIENTS Patients with PD were drawn from a community-based cohort in Rogaland County, Norway. Those who were without cognitive...
متن کاملNeurodegeneration across stages of cognitive decline in Parkinson disease.
OBJECTIVE To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD). DESIGN Images were quantified using a region-of-interest approach and voxel-based morphometry analysis. We used a high-dimensional pattern classification approach to delineate brain reg...
متن کاملFunctional decline in Parkinson disease.
OBJECTIVES To determine the overall rate of functional decline and to assess the progression of different signs of Parkinson disease (PD). PATIENTS AND METHODS Patients with clinically diagnosed PD followed up for at least 3 years were included in this study. Demographic and clinical data (including the Unified Parkinson's Disease Rating Scale [UPDRS]) were analyzed by the multivariate unbala...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2010
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0b013e3181f39a78